Vaping Expected to Increase COPD Health and Economic Burden by 2050
10 sept. 2024 08h00 HE
|
ResMed Inc.
Vaping Expected to Increase COPD Health and Economic Burden by 2050
New ResMed-supported research presented at ERS 2024
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
15 mars 2024 03h05 HE
|
ResMed Inc.
ResMed announced the results of its 2024 Global Sleep Survey, uncovering a world in sleep crisis and encouraging people to discover their sleep superpowers
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21 déc. 2023 08h30 HE
|
Apnimed, Inc.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
31 oct. 2023 20h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed to Participate in Upcoming October Investor Conferences
11 oct. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
10 oct. 2023 08h30 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
01 août 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
16 juin 2023 08h00 HE
|
Incannex Healthcare
MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
ResMed’s Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep
13 mars 2023 07h00 HE
|
ResMed Inc.
81% of respondents experience one or more symptoms indicating poor sleep quality, despite 64% saying they’re satisfied with the quantity of their sleepWomen and older generations are less satisfied...
Narcolepsy Market Growth Sturdy at 9.5% CAGR to Outstrip $4,537.9 Million by 2027 - COVID-19 Impact and Global Analysis by TheInsightPartners.com
18 mai 2021 19h25 HE
|
The Insight Partners
Pune, India., May 19, 2021 (GLOBE NEWSWIRE) -- Narcolepsy Market: Key InsightsAccording to our new research study on “Narcolepsy Market to 2027 – Global Analysis and Forecast – by Type, Product, and...